LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

Home・Elenco Azioni・Cogent Biosciences Inc

Cogent Biosciences Inc

Chiusa

39.15 5.58

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

36.94

Massimo

39.19

Metriche Chiave
By Trading Economics
Entrata	-22M -102M
EPS	-0.5
Dipendenti	258
EBITDA	-30M -109M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+40.8% upside

Dividendi
By Dow Jones
Utili prossimi	5 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	408M 6B
Apertura precedente	33.57
Chiusura precedente	39.15

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

4.88 / 5.87 Supporto e resistenza

Cogent Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 feb 2026, 23:07 UTC

Utili

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 feb 2026, 23:01 UTC

Utili

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 feb 2026, 22:59 UTC

Utili

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24 feb 2026, 22:42 UTC

Utili

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24 feb 2026, 22:24 UTC

Acquisizioni, Fusioni, Takeovers

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24 feb 2026, 23:46 UTC

Discorsi di Mercato

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24 feb 2026, 23:36 UTC

Discorsi di Mercato

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24 feb 2026, 23:30 UTC

Discorsi di Mercato

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24 feb 2026, 23:20 UTC

Discorsi di Mercato

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24 feb 2026, 23:20 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

24 feb 2026, 23:16 UTC

Utili

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24 feb 2026, 23:13 UTC

Utili

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24 feb 2026, 23:12 UTC

Utili

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24 feb 2026, 23:10 UTC

Utili

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24 feb 2026, 23:10 UTC

Utili

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24 feb 2026, 23:08 UTC

Utili

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24 feb 2026, 23:07 UTC

Utili

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24 feb 2026, 22:52 UTC

Utili

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 feb 2026, 22:46 UTC

Utili

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 feb 2026, 22:31 UTC

Acquisizioni, Fusioni, Takeovers

Warner Receives New Bid From Paramount -- 3rd Update

24 feb 2026, 22:29 UTC

Utili

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24 feb 2026, 22:28 UTC

Utili

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24 feb 2026, 22:27 UTC

Utili

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24 feb 2026, 22:27 UTC

Utili

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24 feb 2026, 22:25 UTC

Utili

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24 feb 2026, 22:24 UTC

Utili

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24 feb 2026, 22:23 UTC

Utili

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24 feb 2026, 22:22 UTC

Utili

Woolworths Interim Dividend 45 Australian Cents/Share

24 feb 2026, 22:22 UTC

Utili

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24 feb 2026, 22:21 UTC

Utili

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Confronto tra pari

Modifica del prezzo

Cogent Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

40.8% in crescita

Previsioni per 12 mesi

Media 52.18 USD 40.8%

Alto 67 USD

Basso 35 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

4.88 / 5.87Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.